News

Endocyte has reported the results from phase II clinical study of EC145. The single arm phase II study evaluated the therapeutic agent, EC145 and the molecular imaging agent,

Ranbaxy has received final approval from FDA to manufacture and market Sumatriptan Succinate Tablets, 25mg (base) and 50mg (base). The Office of Generic Drugs, FDA, has determined Ranbaxy

Hospira has reported the US Food and Drug Administration’s approval and launch of oxaliplatin injection in the US. The medication is a generic version of Sanofi-Aventis’ Eloxatin. Hospira’s

Vion Pharmaceuticals has reported a net loss of $6.6m or $0.83 per share for the second quarter of 2009, a decrease when compared to a net loss of

A 96-week study results published in AIDS (the official journal of the International AIDS Society) has shown that Prezista (darunavir) was found to be non-inferior to lopinavir/RITONAVIR. The

Amgen has announced the publication of results from two pivotal phase 3 studies investigating the safety and effectiveness of denosumab at reducing fracture risk, in The New England

Schering-Plough has sealed an agreement with Orchid Chemicals & Pharmaceuticals and Orgenus Pharma, related to the generic manufacturing of certain formulations of CLARINEX (desloratadine). The agreement marks the

PCAS and Nanosyn have signed a joint-venture agreement to operate PCAS-Nanosyn, a Good Manufacturing Practice (cGMP) kilolab in Santa Rosa, Northern California. The newly created company, PCAS-Nanosyn will

Avanir has reported that the investigational drug Zenvia (dextromethorphan/quinidine) has met its primary efficacy endpoint in the confirmatory phase III STAR trial, for the treatment of pseudobulbar affect